MBBC vs RARE · P/E 33, rev $8.8M vs rev $350.0M
Marathon Bancorp, Inc. Common Stock (MBBC) versus Ultragenyx (RARE) — a side-by-side from cached financials, not a winner call.
Marathon Bancorp, Inc. Common Stock (MBBC) is a banks - regional company listed on US.
Ultragenyx (RARE) is a biotechnology company listed on US.
Latest reported MBBC revenue for 2026-03-31 was $8.8M. Net income was $1.4M. Revenue was up 51.0% from 2025-12-31 to 2026-03-31. MBBC currently screens at market cap $29.4M and trailing P/E 33.3.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
MBBC currently screens at market cap $29.4M and trailing P/E 33.3. RARE currently screens at market cap $2.79B.
Not investment advice. Open the MBBC and RARE stock pages for the full models.
Not investment advice.